Buclizine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Buclizine: From Motion Sickness to Allergic Urticaria
One-Sentence Summary
Buclizine is a piperazine-class antihistamine, originally used to treat motion sickness. The TxGNN model predicts it may be effective for allergic urticaria, but only 1 historical publication (1956) and no registered clinical trials currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Motion sickness (the Singapore licence has no approved indication text recorded) |
| Predicted New Indication | Allergic urticaria |
| TxGNN Prediction Score | 98.08% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, buclizine is a piperazine-class first-generation antihistamine (H1 receptor antagonist). Its use in motion sickness is consistent with central H1 and anticholinergic activity, and mechanistically it may be applicable to histamine-mediated conditions such as allergic urticaria.
Allergic urticaria is driven largely by histamine release, and H1 blockade is the standard symptomatic approach. This makes the prediction biologically plausible at the class level. However, the rationale rests on class pharmacology rather than buclizine-specific data.
Several caveats weaken the case. The only supporting document is a 1956 appraisal. Modern second-generation H1 antihistamines are already the established standard of care, so the added value of buclizine is doubtful.
The other predicted indications are weaker still. Cold urticaria (score 96.7%), common cold, nasal cavity disease, pharyngitis and acute laryngopharyngitis have only a class-level symptomatic rationale. Schizophrenia, retinal dystrophy, perisylvian polymicrogyria and X-linked myopia have no plausible mechanistic link and are likely knowledge-graph artifacts. None of these has any trial or literature support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 13294975 | 1956 | Other (historical toxicologic and clinical appraisal; design unclear) | The Journal of Allergy | Toxicologic and clinical appraisal of buclizine as a new antihistaminic compound; no abstract available, and the design cannot be verified |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN02652P | BUCLIZINE TABLET 25 mg (Beacons Pharmaceuticals Pte. Ltd.) | Tablet | Not recorded |
Safety Considerations
Please refer to the package insert for safety information.
No drug-drug interaction records were found in the data compiled for this report. As a first-generation antihistamine, sedation and anticholinergic effects are class concerns that should be confirmed against the label.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is mechanistically plausible for allergic urticaria, but the only supporting evidence is a single 1956 paper with no verifiable design, and there are no registered trials. Established second-generation antihistamines already serve this need, so the incremental value of buclizine is unclear.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (currently a blocking gap for safety screening)
- Detailed mechanism of action data (DrugBank)
- A systematic literature search for modern, controlled evidence of buclizine in urticaria
- A comparison against second-generation H1 antihistamines to show a clear benefit
- The approved indication text for the Singapore licence SIN02652P
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.